论文部分内容阅读
目的 :探讨拉米夫定和阿德福韦酯初始联合与优化治疗失代偿期乙型肝炎肝硬化的临床疗效。方法 :随机抽取我院2014年6月至2015年6月就诊的失代偿期乙型肝炎肝硬化患者92例,按不同治疗方法,将接受初始拉米夫定和阿德福韦酯治疗的患者46例作为观察组,将接受拉米夫定和阿德福韦酯优化治疗的患者46例作为对照组,两组患者均接受保保肝对症支持治疗,治疗48周后,对两组临床效果进行统计对比。结果:观察组治疗后ALT、AST、ALB、TBIL等水平均优于对照组,差异有统计学意义(P<0.05);察组ALT复常率高于对照组,观察组HBV DNA转阴率高于对照组,差异有统计学意义(P<0.05);两组未见明显不良反应发生。结论:对失代偿期乙型肝炎肝硬化患者采取拉米夫定和阿德福韦酯初始联合治疗的临床效果较好,改善患者临床症状,值得临床推荐。
Objective: To investigate the initial curative effect of lamivudine and adefovir dipivoxil in the treatment of decompensated hepatitis B cirrhosis. Methods: A total of 92 patients with decompensated hepatitis B cirrhosis from June 2014 to June 2015 in our hospital were selected randomly. According to different treatment methods, patients receiving initial lamivudine and adefovir dipivoxil treatment Forty-six patients in the observation group received 46 patients who received lamivudine and adefovir dipivoxil-optimized treatment. Patients in both groups were treated with hepatoprotective supportive care. After 48 weeks of treatment, The effect of statistical comparison. Results: The levels of ALT, AST, ALB and TBIL in the observation group were better than those in the control group after treatment (P <0.05), and the recovery rate of ALT in the observation group was higher than that in the control group Higher than the control group, the difference was statistically significant (P <0.05); no obvious adverse reactions occurred in both groups. Conclusion: The initial combination therapy of lamivudine and adefovir dipivoxil in patients with decompensated hepatitis B cirrhosis is better, and clinical symptoms are better. It is worth recommending.